Triple
T20218672
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Air Test and Evaluation Squadron 21 |
E495192
|
entity |
| Predicate | abbreviation |
P43
|
FINISHED |
| Object | VX-21 |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: VX-21 | Statement: [Air Test and Evaluation Squadron 21, abbreviation, VX-21]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: VX-21 Context triple: [Air Test and Evaluation Squadron 21, abbreviation, VX-21]
-
A.
VX-24
VX-24 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft systems and weapons.
-
B.
VX-20
VX-20 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft and aviation systems.
-
C.
VX-31
VX-31 is a United States Navy air test and evaluation squadron responsible for testing and assessing the performance of naval aircraft and related systems.
-
D.
VX-548
VX-548 is an investigational non-opioid pain medication developed by Vertex Pharmaceuticals that targets NaV1.8 sodium channels to treat acute and chronic pain.
-
E.
VX-264
VX-264 is an investigational therapy being developed by Vertex Pharmaceuticals, likely targeting a serious disease area such as cystic fibrosis or another genetic condition within the company’s clinical pipeline.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: VX-21 Target entity description: VX-21 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft, weapons, and related systems.
-
A.
VX-24
VX-24 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft systems and weapons.
-
B.
VX-20
VX-20 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft and aviation systems.
-
C.
VX-31
VX-31 is a United States Navy air test and evaluation squadron responsible for testing and assessing the performance of naval aircraft and related systems.
-
D.
VX-548
VX-548 is an investigational non-opioid pain medication developed by Vertex Pharmaceuticals that targets NaV1.8 sodium channels to treat acute and chronic pain.
-
E.
VX-264
VX-264 is an investigational therapy being developed by Vertex Pharmaceuticals, likely targeting a serious disease area such as cystic fibrosis or another genetic condition within the company’s clinical pipeline.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69da626cff80819097b530718a7c98b6 |
completed | April 11, 2026, 3:02 p.m. |
| NER | Named-entity recognition | batch_69e66edbb67081909c7359ff27205b5f |
completed | April 20, 2026, 6:22 p.m. |
Created at: April 11, 2026, 11:39 p.m.